Interleukin-37: a new molecular target for host-directed therapy of tuberculosis


TB remains to be world’s deadliest infectious disease caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb), which pose a major threat to global public health. The big challenge encountered in current clinical TB is lengthy treatment duration and poor treatment outcomes associated with multidrug-resistant (MDR)/extensively drug-resistant (XDR) TB, and those with comorbidity of TB with HIV and diabetes (WHO, WHO Global Tuberculosis Report 2016). Thus, improved therapeutic strategies are in urgent need for better control and eradication of the disease. There is an increasing awareness that antibiotic treatment is not the only answer to the TB problem, the search for alternative therapy strategies is also important for the success of TB control and therapy.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment